Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; KPG-121 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Kangpu Biopharmaceuticals
- 06 Nov 2019 Planned End Date changed from 1 Dec 2022 to 1 Dec 2020.
- 06 Nov 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2020.
- 06 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Oct 2019 to 30 Nov 2019.